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INTRODUCTION 
 
Biological markers or biomarkers are gaining increasing importance in clinical practice. They 
can be used in many different conditions and for many different purposes. As defined by the 
Biomarkers Definition Working Group in Bethesda, a biomarker is “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention”(1). Biomarkers can be 
analyzed in the serum, in the body fluids, and in tissue specimens, the last being of particular 
importance in pathology since all this material is stored in the pathological Archives.  
In pathology departments and laboratories, many traditional morphological examinations are 
carried out, especially in neoplastic diseases. Nevertheless, many of the classical 
morphological analyses, including staging, grading, vascular invasion and assessment of the 
surgical margins, are not enough anymore to correctly report a tumor. Several subsequent 
clinical decisions are made upon biomarkers that the pathological report should evaluate. A 
paradigm example is represented by the mammary neoplasia, in which a complete evaluation 
of estrogen and progesterone receptors is of mandatory importance in correctly addressing 
patients to tamoxifen therapy (2). Many biomarkers are currently under study, and their 
discovery and subsequent validation may help in better define their patients.  Unfortunately, 
although many markers are discovered, little of them are currently validated for clinical 
practice. One of the reasons is that many of them showed tremendous variations from the 
different studies and cannot be consistently applied. An international Committee from the 
Statistics Subcommitee of the National Cancer Institute-European Organization for Research 
and Treatment of Cancer has developed guidelines, referred to as REMARK, for the reporting 
of tumor marker studies (3). In these guidelines, it is clearly expressed the importance of good 
study design and data quality. Poor study reporting has many negative consequences over the 
research community as a whole. Inappropriately analyzed studies may deserve 
disproportionate clinical attention, just because the results are apparently dramatic; on the 
contrary, carefully designed studies may not attract so much consideration, even if they were 
appropriately conducted, but did not so produce so impressive results (3). Also technical 
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problems may obstacle the results in a validation process of a biomarker, and in particular 
immunohistochemical markers may be affected by preanalytical and analytical problems (4). 
Preanalytical problems include the time to collection, details of fixation, dehydration steps 
and conditions for paraffin-embedding. Analytical issues are represented, most of all, by: 
antigen retrieval techniques, type of detection system, choice of the antibody and material to 
be used (5). 
Biomarkers may be subdivided on the basis of their application: 
 As a diagnostic tool: they help in identifying patients with a disease (diagnostic markers) 
 As a tool for staging a disease or classification of the extent of disease (prostate specific 
antigen, PSA in the blood) 
 As an indicator of disease prognosis (prognostic markers) 
 As an indicator of response to a specific target therapy (predictive markers)(1). 
From a technical point of view, in pathology, biomarkers may be classified in: 
 Immunohistochemical markers 
 Molecular markers 
 
Diagnostic markers 
Biomarkers with diagnostic purposes are extremely important in correctly identifying patients 
carrying the specific disease. Morphological examination may not always reach consistent 
results, especially in small biopsies, with artifactual changes or in difficult cases. By 
immunohistochemistry, alpha-methylacyl-CoA racemase (AMACR) expression is currently 
used as a reliable immunohistochemical diagnostic marker for invasive prostatic carcinoma 
(6). In the next sections, we will also explain our study upon the evaluation of a new 
diagnostic immunohistochemical marker for prostatic carcinoma, which was compared to 
AMACR. Laminin-5 γ2 chain is another important immunohistochemical marker, which may 
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help in identifying  invasiveness in colorectal carcinomas (7), squamous cervical carcinomas 
(8) and glandular cervical adenocarcinomas (9), especially when there is only focal invasion, 
with small aggregates of detached neoplastic cells (budding). 
At the molecular level, FISH (Fluorescence Is Situ Hybridization) may play an important role 
in establishing monosomy in different chromosomes, by using multiple centromeric probes. 
For example, the differential diagnosis between renal oncocytoma and chromophobe renal 
cell carcinoma may be extremely difficult with the morphology, even in association with 
immunohistochemistry (cytokeratin 7, S100A1) and histochemistry (Hale’s colloidal iron 
stain). However, chromphobe renal cell carcinoma frequently exhibits multiple losses among 
whole chromosomes  1, 2, 6, 10, and 17 by FISH (10) and by interphase FISH (11). The more 
complex karyoptypic abnormalities may then address the diagnosis toward a more malignant 
neoplasm, i.e. the chromopohe renal cell carcinoma.  
 
Prognostic markers 
Ki67/MIB1 is a typical prognostic marker and it helps in better identifying grade and 
biological behavior in many malignancies, especially for those located in the central nervous 
system (12).   
By gene expression profiling, diffuse large B cell lymphomas (DLBCL) have been 
extensively studied by Alizadeh et al, who identified two major groups: one group expressed 
genes of germinal centre B cells ('germinal centre B-like DLBCL'), while the other group 
expressed genes normally induced during in vitro activation of peripheral blood B cells 
('activated B-like DLBCL'); patients with germinal centre B-like DLBCL had a significantly 
better overall survival than those with activated B-like DLBCL (13). Similar subgrouping has 
been proposed on the basis of the immunohistochemical results, with comparable findings. 
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Predictive markers 
Paradigm examples are provided by mammary neoplasia, where high expression of estrogen 
and progesterone receptors correlate with tumor responsiveness to the anti-estrogen tamoxifen 
(2). Estrogen and progesterone receptors are also prognostic markers, since they are more 
expressed in many well differentiated neoplasms, with a favorable prognosis. In mammary 
neoplasias, also the amplification of c-erb-B2 is strictly associated with responsiveness to 
trastuzumab. Its amplification status is currently determined firstly with an 
immunohistochemical test, followed by a molecular test for suspicious cases. Molecular 
analysis for amplification of c-cerb-B2 is usually performed with FISH, even if a new dual 
ISH base in chromogenic assay has been recently approved by the Food and Drug 
Administration (FDA). 
Mutated EGFR pulmonary adenocarcinomas may benefit form tyrosine –kinase inhibitor 
(TKI) therapy, such as gefitinib (14) and erlotinib (15). 
 
Molecular pathogenesis: the basis to identify new markers (lesson form the colorectal 
carcinoma) 
The basis for identifying new biological markers is certainly represented by molecular 
carcinogenesis models. Carcinogenesis is a multistep process in which many mutations occur: 
activation of oncogenes, inactivation of oncosuppressor genes and altered expression of DNA 
repair genes. All these molecular modifications determine the loss of growth control from the 
neoplastic cells and, consequently, the neoplastic transformation. A classic example is 
represented by colorectal carcinoma and its multistep carcinogenesis. In colorectal 
carcinogenesis two main molecular pathways are identified (16).  
The first is the classical APC/β-catenin pathway which is particularly involved in familial 
adenomatous polyposis and activated in 80% of sporadic colorectal carcinomas; this pathway 
is characterized by the activation of the Wnt pathway, determines k-ras mutations with EGFR 
activation among the first events and causes p53 mutations in advanced stages. The 
morphological counterpart is exemplified by the classic adenoma-carcinoma sequence. One of 
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the critical target in this first oncogenetic pathway is the possibility to block the EGFR 
signaling induced by k-ras mutations by using anti-EGFR monoclonal antibodies (cetuximab) 
(17); so the k-ras status represents an important predictive marker for responsiveness to this 
drug. Other important factors extensively studied in this pathway are: p53 and VEGF. P53 has 
been shown to be an important prognostic factor in many studies, summarized by meta-
analysis reviews (18). VEGF has been described both as prognostic factor (19;20) and as 
predictive factor to preoperative radiochemotherapy in rectal carcinomas (21).  
The second pathway is the so-called microsatellite instability (MSI) pathway, in which the 
DNA mismatch repair genes are damaged. Deficit in these DNA repair genes causes 
expansion of microsatellite regions. The familial corresponding disease is the Lynch 
syndrome. In sporadic forms, this pathway affects approximately 20% of the colorectal 
carcinomas, mainly mucinous adenocarcinomas. The precursor lesion is frequently the sessile 
serrated adenoma. These lesions are predominately located in the right colon. Molecularly, 
this oncogenetic pathway is characterized by activation of TGFβ and BAX, BRAF mutations, 
MLH1 methylation. In translating these basic concepts into clinical practice, several studies 
have shown that microsatellite instability is both a prognostic and a predictive marker. A 
meta-analysis upon 7642 cases has shown that MSI tumors are associated to a better 
prognosis (22). Microsatellite status is also gaining more and more popularity because of its 
role as predictive factor to response to adjuvant 5-fluorouracil treatment: a study with 570 
cases have attributed to the MSI tumors a less responsiveness to 5-FU treatment (23). We 
have previously reported the role of MUC2 as a predictive marker of responsiveness to 
radiochemotherapy in rectal adenocarcinoma (24); MUC 2 is associated with mucinous 
differentiation and, ultimately, to the MSI. 
Colorectal carcinogenesis has been herein described as an example of a carcinogenetic 
process. The same process may be applied in many other human malignancies, as in oral 
squamous cell carcinoma (OSCC), the central and most important section in this thesis. 
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Statistical consideration 
Statistical validation of a biological marker is one of the most crucial points in determining 
the real reproducibility of the analyses and its effective application. In many cases, the 
statistical analyses are not conducted properly and this may alter the impact of the results. 
Altman et al. reviewed all papers which included analyses of survival data and were published 
in British Journal of Cancer, European Journal of Cancer, Journal of Clinical Oncology and 
American Journal of Clinical Oncology in a 3-month period; they found many problems in 
representing statistical data, in reporting all the variables and not only the p-values, in 
describing all the parameters in the survival curves and in establishing the cut-off points from 
quantitative to qualitative variable transformation (25). 
Survival curves are certainly the gold standard method in order to evaluate a prognostic 
marker (26). They can be used to study survival, disease-free-survival or any time-dependent 
event. With this method the main event on study is time and not the event per se. Graphically, 
survival curves can also give an idea to what is the prognostic impact of any disease. One of 
the most common applications is the comparison between two (or more) survival curves in 
two groups of patients: the “log-rank test”. It is a simple and direct test which may be very 
useful in comparing the survival curves between two groups. However, the best analysis 
would be taken if the two groups would be randomized (27).  Randomization means that the 
two groups are almost equal, expect for the only one difference that we want to analyze.  One 
of the most common mistakes in the medical history is the evaluation of Salk vaccine against 
polio in 1954 (28). The study was designed as follows (28). 
The plan of procedure announced by the National Foundation for Infantile Paralysis 
and its Advisory Committee was to administer vaccine to children in the second grade 
of school; the corresponding first and third graders would not be inoculated but would 
be kept under observation for the occurrence of poliomyelitis in comparison with the 
inoculated second graders. This has been designated the "Observed Control" study. 
In observed areas where only those second grade children whose parents requested 
participation were vaccinated, the problem of establishing the control population was 
more complex. 
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In this study, even if this was one of the biggest trials worldwide at that time, the concept of 
randomization was totally lacking. Only the second year school children whose parents gave 
consent were vaccinated and the first and third year of all children represented the control 
group. The main problems were two. Firstly, the groups were composed of children of 
different ages; secondly, children from a poor social background were more exposed to polio 
antigen and their parents more favorable to assign them to the vaccine. So children who were 
vaccinated were at higher risk to develop the disease. The results showed paradoxically that 
Salk vaccine enhanced the risk of developing polio disease! This episode underlines the 
importance of a correct randomization in comparing two groups. Ideally, the two groups 
should be equal and differ only for the characteristic we would like to study. Unfortunately, 
this situation is very difficult to realize in the clinical practice, but enormous problems may be 
present when there are many differences between the two groups.  
When comparing more variables at the same time, a common procedure is to evaluate 
survival function with multivariate analysis; the most common method is the use of Cox 
regression (26). The different variables used in the multivariate analysis should be 
independent one form the other. Alternatively, many problems and confounding factors may 
develop. 
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The aim of the project was to identify immunohistochemical and molecular markers which 
may be useful in correctly identify neoplastic diseases. 
We subdivide the work in three main sections: 
1) IGFBP2 as a diagnostic marker in prostatic carcinoma. 
2) Heparan-sulfate proteoglycans as prognostic markers and their predictive role to 
responsiveness to adjuvant radiotherapy in oral squamous cell carcinomas. 
3) EGFR as predictive markers for responsiveness to tyrosine-kinas inhibitors in 
pulmonary adenocarcinomas. 
AIM S OF THE PROJECT 
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Insulin-like growth factors (IGFs) and insulin-like growth factor binding proteins (IGFBPs) 
play a central role in cellular growth, and in normal and neoplastic development. 
IGFBP2 has been shown to be hyper-expressed in many human malignancies, including 
ovarian carcinoma (29), colorectal carcinoma (30), hepatocellular carcinoma (31) and 
neuroblastoma (32). In addition, IGFBP2 has been shown to be highly expressed in 
glioblastoma, both genetically and immunohistochemically (33). IGFBP2 has even been 
considered to be a therapeutic target in neoplastic cell lines derived from breast carcinoma, 
both directly (34) and by modulation of the immune system (35). Furthermore, serum levels 
of IGFBP2 are reduced in mammary carcinoma (36) and increased in ovarian carcinoma (37), 
suggesting its possible role as a serological marker for early diagnosis.  
In prostatic tissues, genetic profiling studies documented that IGFBP2 was among the genes 
overexpressed in malignant lesions in comparison to normal cases (38-40). 
Immunohistochemically, IGFBP2 has been found to be highly reactive in prostatic 
adenocarcinoma (PAc) (41-43). IGFBP2 has been proposed as a serum prognostic marker for 
patients affected by PAc (44). A significant association between elevated serum levels of 
IGFBP2 and the presence of PAc, especially when it is in advanced stages (45-47), has been 
documented. Yu et al. have shown that serum levels of IGFBP2 were higher in patients with 
remission than in patients with relapse (48).  However, Roddam and colleagues (49) and a 
meta-analysis conducted by Rowlands et al. (50) did not find a strong association between 
IGFBP2 serum levels and prostate cancer risk. 
Nevertheless, presently IGFBP-2 is rarely applied in routine diagnoses. Alpha-methylacyl-
CoA racemase (AMACR) is currently used as an immunohistochemical marker for PAc, 
especially in biopsies with small acinar lesions suspicious for malignancy (51). However, 
AMACR is frequently expressed in high-grade prostatic intraepithelial neoplasia (HG-PIN) 
and, to some extent, also in some benign lesions (52), thus sometimes making the 
IGFBP2 AS A DIAGNOSTIC MARKER IN PROSTATIC ADENOCARCINOMAS 
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interpretation of the immunohistochemical results difficult. Therefore, it would be important 
to find other possible diagnostic markers which could help in the diagnosis of malignancy. 
The aim of the study was to evaluate the diagnostic value of IGFBP2 expression in normal 
epithelium, HG-PIN and PAc, both in patients hormonally untreated and in patients having 
undergone complete androgen ablation. Results were compared with Alpha-methylacyl-CoA 
racemase (AMACR). 
 
Materials and methods 
Sixty prostatectomy specimens were utilized in this study. The specimens represented the 
following three groups: 
 Group 1: 10 consecutive simple prostatectomy specimens from patients with bladder 
outlet obstruction due to benign prostatic hyperplasia; 
 Group 2: 40 consecutive radical prostatectomy specimens with prostatic carcinoma 
from patients hormonally untreated before surgery. Preoperative biopsies were 
available for all the cases; 
 Group 3: 10 consecutive radical prostatectomies with prostatic carcinoma from 
patients who underwent complete androgen ablation three months before surgery. 
Preoperative biopsies were available in all cases.  
The cases of Groups 1 and 2 were retrieved from the files of the Section of Anatomic 
Pathology “Marcello Malpighi” of the University of Bologna, whereas those of Group 3 were 
from the United Hospitals-Polytechnic University of the Marche Region, Ancona. All cases 
had been fixed in 10% buffered formalin and paraffin embedded. Five mm thick sections 
were stained with hematoxylin and eosin (H&E). For the purpose of this study, the slides of 
all cases of the three groups were re-examined by two of the authors (AAS and MPF). The 
cases of Group 1 did show neither PAc nor HG-PIN. For the cases of Groups 2 and 3, the 
samples with PAc were from the peripheral zone. The pathological stage was based on the 7
th
 
2009 revision of the TNM (53). The Gleason score of the cancers of Group 2 was based on 
the ISUP 2005 modification (54). Due to the neoadjuvant therapy, the Gleason grading 
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system was not applied to the cases of Group 3. The presence of HG-PIN was recorded for the 
cases of Groups 2 and 3. 
 
Immunohistochemistry 
Immunohistochemical analysis for IGFBP2 (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA, dilution 1:100) and for AMACR (Cell Marque, Rocklin, CA, U.S.A., dilution 1:100) 
was performed. Antigen retrieval was obtained by pre-treatment in W-CAP citrate buffer pH 
6.0 for IGFBP2 and in W-CAP TEC buffer pH 8.0 for AMACR (Bio-Optica Milano SpA, 
Milan, Italy) at 98°C for 25 minutes. Inhibition of endogenous peroxidases was performed in 
3% H2O2 solution. After rinsing the slides in phosphate-buffered saline (PBS) 1x solution 
with 0.1% solution of detergent Tween 20 (phosphate-buffered saline–Tween 20; Bio-
Optica), the sections were incubated in a humid chamber at room temperature for 5 minutes 
with Ultra V Block solution (Ultravision LP, LabVision Corporation, Thermo Fisher 
Scientific Inc. Fremont, CA, U.S.A.). They were subsequently incubated in the humid 
chamber at 4°C for 6 hours with primary antibody for IGFBP2 and at room temperature for 1 
hour with primary antibody for AMACR. Sections were then washed in buffered solution and 
incubated in the humid chamber at room temperature for 20 minutes with primary antibody 
enhancer solution (Ultravision LP, LabVision Corporation). After several washes in buffered 
solution, the sections were incubated for 30 minutes in horseradish peroxide (HRP) 
(Ultravision LP, LabVision Corporation) polymer solution. Reaction was revealed with 
diaminobenzidin (DAB) solution for 3 minutes and counterstained with hematoxylin. 
 
Evaluation of immunohistochemistry 
For each immunohistochemical marker, the percentage of positive cells was calculated in 
prostate cancer, HG-PIN and normal looking epithelium in Groups 2 and 3 as well as in 
normal tissue in Group 3. In order to consider not only the percentage of positive neoplastic 
cells but also their staining intensity, we also estimated the immunohistochemical score, 
according to McCarthy’s scoring system, originally performed on breast neoplasia (55) and 
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subsequently also applied to prostate carcinoma (56). The immunohistochemical score was 
calculated as follows: percentage of positive neoplastic cells multiplied by the staining 
intensity (0: none; 1: weak; 2: moderate; 3: strong). It ranges from 0 to 300. The mean and 
standard deviation (SD) were determined for the percentages of positive cells and their 
immunohistochemical scores for both IGFBP2 and AMACR in the three groups.  
 
Statistics  
Statistical analysis was carried out with the statistical package SPSS 13.0 for Windows (SPSS 
Inc., Chicago, IL, U.S.A.). It included ROC (receiver-operator characteristic) curves, the 
Wilcoxon signed rank test and the Spearman rank test. The differences between the groups 
were considered statistically significant at a value of p<0.05. 
 
Results 
1) Group 1 (patients with bladder outlet obstruction) 
The ducts and acini of all cases of Group 1 with the exception of one were negative for 
IGFBP2. A weak positivity for IGFBP2 was seen in urothelial metaplasia and periurethral 
glands. Stromal and endothelial cells were negative. An identical staining pattern was seen in 
the normal looking ducts and acini of Groups 2 and 3. Among normal ducts and acini, 
scattered cells were intensely stained (data not shown). In deeper sections, the cells in the 
same location were Chromogranin A positive and thus interpreted as neuroendocrine (NE) 
cells.  
As far as AMACR was concerned, normal tissue in the three groups was negative, both in 
biopsies and in surgical specimens. 
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2) Group 2: Patients hormonally untreated before surgery  
Prostate cancer 
IGFBP2 was positive in the cytoplasm of all 40 cases of PAc, both in the preoperative 
biopsies and in the surgical specimens. The percentage of neoplastic cells immunoreactive for 
IGFBP2 ranged from 10 to 90% in the biopsies (mean 66%, SD 22%) and from 10 to 80% in 
the surgical specimens (mean 59%, SD 21%). The immunohistochemical score for IGFBP2 
ranged from 10 to 270 in the biopsies (mean 152, SD 82) and from 20 to 240 in the surgical 
specimens (mean 142, SD 68). 
AMACR was positive in all cases (40/40) of PAc. The percentage of neoplastic cells positive 
for AMACR ranged from 20 to 90% in the biopsies (mean 80%, SD 14%) and from 50 to 
90% in the surgical specimens (mean 79%, SD 12%), while the immunohistochemical score 
ranged from 20 to 270 in the biopsies (mean 210, SD 63) and from 50 to 270 in the surgical 
specimens (mean 205, SD 56). 
No significant correlation was found between IGFBP2/AMACR immunohistochemical scores 
and the Gleason score, neither in the biopsies (ρ=-0.52 for the Gleason score and p=0.750 for 
the IGFBP2 immunohistochemical score; ρ=-0.64 for the Gleason score and p=0.693 for the 
AMACR immunohistochemical score) nor in the surgical specimens (ρ=-0.89 for the Gleason 
score  and p=0.585 for the IGFBP2 immunohistochemical score; ρ=0.001 for the Gleason 
score and p=0.994 for the AMACR immunohistochemical score). In the surgical specimens, 
no correlation was found between IGFBP2/AMACR immunohistochemical scores and the 
corresponding pathological stage (ρ=-0.245 for the stage and p=0.312 for the IGFBP2 
immunohistochemical score; ρ= -0.156 for the stage and p=0.523 for the AMACR 
immunohistochemical score).  
 
HG-PIN  
In HG-PIN, a subtle positivity for IGFBP2 was detected in all but 1 biopsy and in all but 4 
surgical specimens. The percentage of positive HG-PIN cells for IGFBP2 ranged from 10 to 
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70% (mean: 25%; SD: 25%) in the biopsies and from 5 to 80% (mean: 18%; SD: 20%) in the 
surgical specimens. The immunohistochemical score ranged from 5 to 100 (mean: 47; SD: 52) 
in the biopsies and from 5 to 160 (mean: 39; SD: 47) in the surgical specimens. 
The positivity for AMACR in HGPIN was observed in all but 1 biopsy and in all but 1 
surgical specimen. The percentage of positive HG-PIN cells for AMACR ranged from 10 to 
90% (mean: 55%; SD: 29%) in the biopsies and from 10 to 80% (mean: 34%; SD: 26%) in 
the surgical specimens, while the immunohistochemical score for AMACR ranged from 10 to 
270 (mean: 114; SD: 77) in the biopsies and from 10 to 240 (mean: 76; SD: 71) in the surgical 
specimens. 
 
Statistical analysis 
According to the ROC curve analysis, by examining the percentages of positive neoplastic 
cells, the overall accuracy (as expressed by the area under each curve) in detecting invasive 
PAc vs. HG-PIN was higher for IGFBP2 than for AMACR. The area under the ROC curve 
was higher for IGFBP2 than for AMACR, both in the biopsies (0.914 for IGFBP2 and 0.787 
for AMACR) and in the surgical specimens (0.906 for IGFBP2 and 0.887 for AMACR). 
Cut-off values for IGFBP2 positivity in discriminating PAc vs. HG-PIN were determined if 
greater than or equal to 25% of the lesional cells (sensitivity: 0.950, 1-specificity: 0.421 in the 
biopsies; sensitivity: 0.875, 1-specificity: 0.211 in the surgical specimens). A lesion can be 
then considered highly suspicious for HG-PIN when less than 25% of the lesional cells are 
positive for IGFBP2. Cut-off values for AMACR were not identified since they were more 
difficult to determine and generally higher, the overall performance of the test also being 
lower than for IGFBP2. 
According to the Wilcoxon signed rank test, by examining both the percentages of positive 
neoplastic cells and their corresponding immunohistochemical scores, IGFBP2 in comparison 
to AMACR revealed fewer neoplastic cells not only in invasive PAc, but also in HG-PIN. In 
invasive PAc, IGFBP2 detected fewer neoplastic cells than AMACR, both in the biopsies 
(Z=-3.213, p=0.001 by percentage of positive neoplastic cells; Z=-3.006, p=0.003 by their 
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immunohistochemical scores) and in the surgical specimens (Z=-4.127, p<0.001 by 
examining the percentage of positive neoplastic cells; Z=-4.015, p<0.001 by 
immunohistochemical score). A similar reduction was also observed in HG-PIN, both in the 
biopsies (Z=-3.595, p<0.001 by percentage of positive neoplastic cells; Z=-3.600, p<0.001 by 
immunohistochemical score) and in the surgical specimens (Z=-3.001, p=0.003 by percentage 
of positive neoplastic cells; Z=-2.760, p=0.006 by immunohistochemical score). 
 
3) Group 3: Patients who underwent androgen ablation before surgery  
Prostate cancer 
Immunohistochemical expression of IGFBP2 in PAc was detected in all (10/10) cases in the 
biopsies and in 9 out of 10 in the surgical specimens (Figure 1). In particular, the percentage 
of neoplastic cells immunoreactive for IGFBP2 ranged from 10 to 90% (mean 41%, SD 26%) 
in the biopsies and from 5 to 70% in the surgical specimens (mean 24%, SD 25%). The 
immunohistochemical score ranged from 10 to 180 in the biopsies (mean 76, SD 69) and from 
10 to 210 in the surgical specimens (mean 52, SD 69).  
Immunoreactivity for AMACR was observed in PAc in all (10/10) cases, in the biopsies and 
the surgical specimens. The percentage of neoplastic cells positive for AMACR ranged from 
50 to 90% in the biopsies (mean 79%, SD 12%) and from 10 to 90% in the surgical specimens 
(mean 48%, SD 28%), while the immunohistochemical scores varied from 100 to 270 in the 
biopsies (mean 184, SD 57) and from 10 to 270 in the surgical specimens (mean 105, SD 75). 
 
HG-PIN 
HG-PIN was seen in 2 biopsies and in 5 surgical specimens.  
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Discussion 
The results obtained in the present study showed that IGFBP2 is consistently positive in PAc, 
while it is negative in benign prostatic tissues.  
Three other studies have documented consistent immunoreactivity for IGFBP2 in invasive 
PAc (57-59). However, differences have been noted in examining IGFBP2 expression in HG-
PIN. The current investigation shows that IGFBP-2 is expressed in HG-PIN, but at a lower 
level than in PAc. Tennant and coworkers reached a similar conclusion by examining 28 
prostatectomy specimens with adenocarcinoma; they identified weak immunoreactivity for 
IGFBP2 in normal epithelium, moderate staining in PIN and strong or very strong expression 
in adenocarcinoma (60). In another study conducted by the same group on 24 prostatic 
specimens (with 20 adenocarcinomas), comparable results were obtained since IGFBP-2 
immunoreactivity increased from the normal through the premalignant (i.e., HG-PIN) and into 
the malignant states (i.e., PAc) (61). Richardsen et al. confirmed negativity or very weak 
expression in normal epithelium and in benign prostatic hyperplasia (62); however, they did 
not find any differences between HG-PIN and carcinoma, and they described the 
overexpression of IGFBP2 in both HG-PIN and carcinoma; in different cases, the intensity 
varied from weak to moderate to strong, and the pattern varied from diffuse granular staining 
to strong cytoplasmic staining (63).  
The present data failed to find any correlation between IGFBP2 expression and Gleason grade 
or tumor stage. This is comparable to the three above-mentioned studies (64-66). However, 
considering total IGFBP2 RNA expression in neoplastic tissue, Figueroa et al. detected 
significantly higher RNA expression of IGFBP-2 in tumors with a high Gleason score in 
comparison to tumors with a low score and benign tissue (67). 
The present study shows that IGFBP-2 is strongly expressed in the NE cells present in benign 
prostatic glands. Cells in a similar location do not express AMACR. This finding is similar to 
that seen previously by Richardsen et al (68). Furthermore, Tennant et al. described very 
strong immunoreactivity in scattered stromal cells (69), which may represent what we 
interpreted as NE cells. Previous studies suggested a role of IGFBP2 in stimulating 
proliferation of prostatic cells (70;71). It is not easy to understand the meaning of IGFBP2 
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expression in NE prostatic cells, but it may represent a further proof of IGFBP2 involvement 
in growth stimulation.  
In cases of Group 3 (i.e. patients following complete androgen ablation), the expression of 
IGFBP2 was consistently detected in the initial diagnostic biopsies, but markedly reduced in 
the surgical specimens after hormonal treatment. The expression of AMACR was also 
reduced, but at a lower level than that of IGFBP2. Interestingly, androgen ablation did not 
affect IGFBP2 expression in the NE cells, while AMACR remained negative in the NE cells.  
This is among the first studies to document the immunoreactivity for IGFBP2 of PAc 
following complete androgen ablation. Bubendorf et al. demonstrated that IGFBP2 was 
genetically overexpressed in a hormone refracting cell line of prostate cancer; on a tissue 
microarray, they also observed consistent immunoreactivity for IGFBP2 in all tumors which 
had developed a recurrent tumor during androgen deprivation therapy (72). Similar 
conclusions were noted by Kyiama et al., who found that IGFBP2 mRNA and protein levels 
increased 2–3-folds after androgen withdrawal in LNCaP (an androgen-sensitive human 
prostatic carcinoma cell line); they also identified increased IGFBP-2 immunohistochemical 
levels after castration using a human prostate tissue microarray of untreated and posthormone 
therapy treated prostatectomy specimens (73). Other experimental studies on cancer cell lines 
showed that stimulation by IGFBP2 had a potent stimulatory effect on the growth of LAPC-4 
(an androgen-dependent cell line) prostate cancer cells, this effect being more pronounced in 
the absence of androgens (74). Inman et al. investigated the serum level of IGFBP2 following 
androgen ablation (75) and they found that high serum levels of IGFBP2 were associated with 
a better prognosis in patients who received hormonal neoadjuvant therapy and with a worse 
prognosis in patients who did not receive any preoperative treatment (76). All these findings 
may support a possible interaction between IGFBP2 and the androgen receptor system.  
All these results lead to two considerations. One is that IGFBP2 is a good 
immunohistochemical marker in the identification of PAc. This concept is also sustained by 
the role played by IGFBP2 as a serum marker (both diagnostic and prognostic) for PAc (77-
83). The other is the fact that IGFBP2 could be involved not only in the transition from HG-
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PIN to PAc but also, through the action of the NE cells, in the progression of PAc towards an 
androgen-independent phase, as demonstrated in those cases with NE differentiation (84-86). 
 
In conclusions the principal findings in the current study were: 
 IGFBP2 is not expressed in the normal-looking tissue of the transition and peripheral 
zones; 
 IGFBP2 is expressed in the cytoplasm of untreated PAc and, to a lesser extent, in HG-
PIN 
 IGFBP-2 is also expressed in PAc and HG-PIN following complete androgen ablation, 
but to a lesser extent than in the untreated neoplasms; 
 IGFBP2 expression in the untreated specimens is lower in HG-PIN than in invasive 
PAc. This finding can be of diagnostic help especially in thin pre-operative needle 
biopsies, when a small amount of tissue is available for immunohistochemical 
stainings. 
 Neuroendocrine cells present in prostatic glands are immunoreactive for IGFBP-2 
(87). 
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Figure 1. IGFBP2 as a diagnostic marker for prostatic adenocarcinoma (PAc).  
Group 3: patients who underwent androgen ablation before surgery.  
In biopsies, invasive PAc (a) highly expresses both IGFBP2 (b) and AMACR (c). In surgical 
specimens, invasive PAc after androgen ablation (d) shows a markedly lowered expression of 
IGFBP2 (e) while AMACR immunoreactivity is still detectable (f).
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Oral squamous cell carcinoma (OSCC) is a major disease, with estimated 263,000 new cases 
worldwide per year (88). In pathological evaluation of OSCC, two of the most critical 
prognostic points are stage (89;90) and Brodman’s grade (91). Other important morphological 
factors that may play an important role at the morphological evaluation are: tumor thickness 
and depth of invasion (92;93), desmoplastic reaction of the surrounding stroma (94), tumor 
associated tissue eosinophilia (95), vascular and/or perineural invasion. 
Molecular carcinogenesis in oral squamous cell carcinoma is a step by step process, which 
involves numerous factors (96;97), similarly to the colorectal carcinogenesis described in the 
introduction section. From this step-by-step process, many factors have been identified, and 
some of them deserve special attention because of their prognostic value. Prognostic factors 
extensively studied are: p16 (98), p53 and p63 (99), cyclin D1 (100). Lymph node metastasis 
is certainly one of the histopathological parameters that primarily affect prognosis, but many 
cases and especially small tumors still have undetectable nodal disease (101). Despite the 
recent diagnostic and therapeutic improvements, factors determining metastatic disease are 
mostly unknown.  
Proteoglycans (PGs) are glycoproteins with one or more covalently attached heparin sulfate 
chains (102). On the basis of their core protein primary structure, they are classified in cell 
surface PGs, extracellular PGs, and intracellular PGs (103). Cell surface PGs are either 
integral membrane PGs or are linked to the membrane via a phosphatidylinositol moiety;  
they appear to serve as receptors for growth factors and other components of the extracellular 
matrix, for cell-matrix and cell-cell interactions and as receptors for other cell-cell interaction 
molecules (104). The major cell surface PGs are syndecans and glypicans (105;106). The 
syndecan (SYN) family comprises four integral membrane proteins, named SYN-1 to SYN-4 
(107). In the glypican (GPC) family there are six family members, known as GPC-1 to GPC-6 
(108). Another important cell surface proteoglycan is NG2 (109;110). 
HEPARAN SURFACE PROTEOGLYCANS IN ORAL SQUAMOUS CELL 
CARCINOMAS AS PROGNOSTIC MARKERS AND THEIR PREDICTIVE ROLE 
TO ADJUVANT RADIOTHERAPY 
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Several studies have demonstrated the important role played by cell surface PGs in promoting 
cell growth and development in human development and in neoplastic events (111;112). In 
OSCC, immunohistochemical investigations have shown that SYN-1  staining intensity is 
associated with keratinocyte differentiation and clinical outcome, both in epithelial neoplastic 
cells (113;114), and in the stroma (115). SYN-2 may function as a cell surface receptor in 
highly migratory tumor cells (116). Several studies suggested that GPC-3 could act as a tumor 
suppressor gene (117;118). In culture cell studies, NG2 expression is related to tumor 
initiations and growth rate, predisposing to poorer prognosis (119). 
Aim of the present study is to define the molecular and immunohistochemical expression of 
cell surface PGs in OSCC, both in epithelial neoplastic cells and in the accompanying stroma, 
and to establish possible relationship with the clinical outcome. 
 
Materials and methods 
Patient selection 
A total of 150 cases of OSCC were obtained from the files of the Departments of Surgical 
Pathology of the Universities of Bologna and Parma (Italy). Patients were surgically treated 
by three groups of Maxillo-Facial surgeons from Bologna (University of Bologna at 
Polyclinic S.Orsola-Malpighi and Bellaria Hospital) and Parma (University of Parma), 
applying the same surgical procedures. 
Criteria of selections were the follows: a) all cases were primary OSCC (assessed by pre-
operative biopsy), not previously treated by radio or chemotherapy; b) fresh frozen tissue was 
available for molecular studies. 
Follow up information was available in 93 patients for a period ranging from 6 to 34 months 
(mean: 19, SD: 7). 
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Adjuvant therapies 
In selected patients, especially in those affected by advanced disease, adjuvant postoperative 
treatments were performed. Chemotherapy consisted of 5-fluorouracil and cisplatinum. Radio 
therapy was composed of 60 Gy administered in 30-33 sections. 
 
Tissue microarray (TMA) construction 
From each case, the block containing representative neoplastic tissue was selected. In order to 
have uniform immunohistochemical characterization of all cases, tissue micro-arrays (TMAs) 
were constructed. TMA construction was performed following a previously described 
procedure (120-122). Briefly, a new cut haematoxylin and eosin-stained section was obtained 
from each paraffin block and used to define diagnostic areas. Subsequently representative 0.6 
mm cores were obtained from each case, and inserted in a grid pattern into a recipient paraffin 
block using a tissue arrayer. Cases were considered representative when at least 50% of the 
section was composed of neoplastic tissue. For each case, the core with the highest percentage 
of tumor cells stained was used for analysis.  
 
Immunohistochemistry 
Sections (4 µm) were cut from TMA and stained with the antibodies listed in Table 1. 
Immunohistochemistry was performed as follows: dewaxing and antigens unmasking 
occurred simultaneously with the solution W-Cap TEC buffer pH 6 or W-Cap TEC buffer pH 
8 (Bio-Optica, Milan, Italy) for 25 minutes at 98° C. The endogenous peroxidases inhibition 
was performed by 10 minutes incubation with H2O2 (3% in H2O), washing in distilled water 
and incubating for 5 minutes with Blocking Solution (LabVision, Fremont, CA, USA) to 
induce the non-specific binding sites saturation; both steps occurred at room temperature. 
Primary monoclonal antibodies, listed in Table 1, were applied on sections for 60 minutes at 
room temperature. Following, chromogenic detection was performed using the UltraVision 
Detection System (LabVision, Fremont, CA, USA), which provided incubation with Antibody 
Enhancer for 20 minutes followed by HRP-Polymer for 30 minutes. Finally, DAB chromogen 
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(Dako, Carpenteria, CA, USA) was applied for 3-5 minutes and sections were counterstained 
with hematoxylin after washing with water.  
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Table 1. List of all antidodies used. Legend: SYN syndecan, GPC glypican. 
 
Antibody Clone 
Manufacturer 
Dilution 
Antigen 
Retrieval 
SYN-1 MI15 Dako 1:100 W-CAP pH 6 
SYN-2 1F10/B8 Santa Cruz Biotechnology 1:50 W-CAP pH 8 
SYN-3  
Sigma Aldrich (Powered by 
AtlasProtein) 
1:50 W-CAP pH 8 
SYN-4 H-140 Santa Cruz Biotechnology 1:100 W-CAP pH 8 
GPC-1 4D1 Millipore 1:50 W-CAP pH 6 
GPC-3 1G-12 Biomosaics 1:250 W-CAP pH 6 
GPC-4 (aa 
54-66) 
 
Immundiagnostik 
1:500 W-CAP pH 8 
GPC-6  
Sigma Aldrich (Powered by 
AtlasProtein) 
1:20 W-CAP pH 8 
NG2 132.38 Sigma Aldrich 1:50 W-CAP pH 6 
4D1 surnatant 
Handle 
Made 
 
1:5 W-CAP pH 8 
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Immunohistochemical evaluation 
The evaluation and scoring of the immunohistochemical results were performed with a light 
microscope (Nikon) at a magnification of 40Χ. Each antigen expression was 
semiquantitatively evaluated and scored as follows: 
 Score 0 (-)  = no positive cells were detected 
 Score 1 (+\-)  = <10% of cells were positive  
 Score 2 (+) = 10-50% of cells were positive  
 Score 3 (++) = >50% of cells were positive  
 Score 4 (+++) = >90% of cells were positive  
 
Statistical analysis 
For each case, mean and standard deviation (SD) of all variables was determined. Spearman’s 
rank order correlation (ρ) was calculated among the different immunohistochemical scores 
and differentiation grade, in order to detect possible relationships among them.  
Overall survival and disease-free specific survival were analyzed in both univariate and 
multivariate analyses. Single factors were analyzed with univariate analysis and the statistical 
significance was calculated with log rank test. Group of factors were studied together in 
multivariate analysis and their statistical significance was calculated with Cox regression 
analysis. In multivariate analyses, many different models were tested, with different 
combinations. The main models were: 12 independent variables (SYN-1, SYN-2, SYN-3, 
SYN-4, GPC-1, GPC-3, GPC-4, GPC-6, 4D1 surnatant in the epithelial neoplastic cells, and 
SYN-1, SYN-2 , GPC-1 in the stroma),  6 independent syndecan variables (SYN-1, SYN-2, 
SYN-3, SYN-4, in the epithelial neoplastic cells, and SYN-1, SYN-2 in the stroma), 4 
independent syndecan variables (SYN-1, SYN-2, in the epithelial neoplastic cells, and SYN-
1, SYN-2 in the stroma) . For the validity of the regression models, GPC-4 expression in the 
stroma was removed from the variables, because it was correlated with GPC expression in the 
epithelial cells. NG2 was also not included, because too few measurements were performed. 
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All data were analyzed with SPSS 13.0 for Windows (SPSS Inc., Chicago, IL, USA). 
Statistical significance was taken at p value (two-tailed) less than 0.05.  
 
Results 
Clinical and pathological features 
Patients were 62 females and 88 males, with age varying from 27 to 93 (mean 62; SD 14). 
Smoke and alcohol consumption was known in 86 patients, among which 54 were habitual 
smokers and 44 referred regular alcohol consumption.  
With the 2010 TNM staging system (53), cases were classified as follows:  41 pT1, 54 pT2, 
13 pT3, and 42 pT4; 88 pN0, 27 pN1, 31 pN2, 2 pNx; 35 stage I, 28 stage II, 27 stage III, 57 
stage IV.  
Lymph node metastases were detected in 60 cases at presentation, and in 4 cases in the FU; in 
2 cases no lymph node was resected.  
Follow up revealed local recurrence in 10 cases, 3 cases with lymph node metastasis, 1 case 
with local recurrence and lymph node metastasis; among all of them, 11 patients were 
deceased (1 with esophageal carcinoma). In 71 patients no recurrence and/or metastasis was 
documented. 
In the constructed TMA, 3 cases were composed of carcinoma in situ, among them 1 case was 
composed only of in situ carcinoma; 1 case did not contained sufficient material. 
Representative sections for all markers under study were available in 148/148 invasive 
OSCCs. 
 
Immunohistochemical features in invasive carcinoma (148 cases)  
SYN-1 (CD138). The staining was predominantly observed with a cell membrane pattern.  
The epithelial neoplastic cells were positive for SYN-1 in 133/148 cases (Figure 1a), while 
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the stromal component was positive in 31/148 cases (Figure 1b). Staining was mainly 
localized in keratinizing neoplastic cells, located at the center of the neoplastic nests. 
SYN-2. The staining was predominantly observed with a cell membrane pattern. SYN-2 was 
positive in the epithelial neoplastic cells in 21/148 cases (Figure 1c). The stromal cells were 
positive in 108/148 cases (Figure 1d). Staining increased when desmoplastic stroma appeared. 
Furthermore, SYN-2 marked the thin stromal vessel walls in 45/148 cases. 
SYN-3. The staining was predominantly observed with a diffuse cytoplasmic pattern and focal 
membrane reinforcement. This marker was positive in the epithelial neoplastic cells in 54/148 
cases. No reactivity was detected in the stroma. 
SYN-4. The staining was predominantly observed with a diffuse cytoplasmic pattern and focal 
membrane reinforcement. In the epithelial neoplastic cells, SYN-4 was positive in 31/148 
cases. No reactivity was detected in the stroma. 
GPC-1. The staining was predominantly observed with a diffuse cytoplasmic pattern and 
membrane reinforcement. In the epithelial neoplastic cells, GPC-1 was positive in 111/148 
cases (Figure 2a). Stromal reactivity was strongly seen only in 8/148 cases. 
GPC-3. The staining was predominantly observed with a diffuse cytoplasmic pattern and 
membrane reinforcement (Figure 2b). In the epithelial neoplastic cells, GPC-3 was positive in 
27/148 cases. No reactivity was detected in the stroma. 
GPC-4. The staining was predominantly observed with a diffuse cytoplasmic pattern.  In the 
epithelial neoplastic cells, GPC -4 was positive in 55/148 cases (Figure 2c). In the stroma, 
27/148 cases exhibited diffuse immunoreactivity. 
GPC -6. The staining was predominantly observed with a granular cytoplasmic pattern.  In the 
epithelial neoplastic cells, GPC-6 was positive in 54/148 cases. No reactivity was detected in 
the stroma. 
NG 2. The staining was predominantly observed with a nuclear pattern. In the epithelial 
neoplastic cells, NG2 was positive in 35/36 cases. No reactivity was detected in the stroma. 
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4 D1 surnatant. The staining was predominantly observed with a granular cytoplasmic 
pattern. The epithelial component was negative in all 98/98 cases. In the stromal component, 
4 D1 was positive only in stromal cells in 18/148 cases (Figure 2d).  
 
Immunohistochemical features in carcinoma in situ 
The 3 cases composed of carcinoma in situ showed moderate/diffuse staining for SYN-1 and 
GPC-1 in the epithelial neoplastic cell. The other markers were negative, both in the epithelial 
neoplastic cells and in the stroma.  
 
 
Figure 2. Immunohistochemical expression of syndecans. 
Syndecan-1 (SYN-1) immunoreactivity in epithelial neoplastic cells (a) and in stromal cells 
(b); syndecan-2 (SYN-2)  immunoreactivity in epithelial neoplastic cells (c) and in stromal 
cells (d). 
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Figure 3. Immunohistochemical expression of glypicans and 4 D1. 
Immunohistochemical expression of glypican-1 (GPC-1) (a), glypican-3 (GPC-3) (b) and 
glypican-4 (GPC-4) (c) in epithelial neoplastic cells; 4D1 surnatant is expressed only in 
stromal cells (d).  
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Statistical analysis 
Statistical analysis was carried out only in invasive carcinoma (148 cases). The strongest 
correlation among the immunohistochemical scores was found between GPC-4 expression in 
the epithelial neoplastic cells and GPC-4 expression in the stroma (ρ= 0.775, p < 0.0001).  
In cases analyzed with all data and available follow-up, survival multivariate analysis with 
Cox regression model revealed a statistical significance between syndecan 1 expression and 
reduction of overall survival. In such association we can appreciate 0.046 p-value with 1.967 
odds radio. This is the summary of the analysis (Table 2). 
 B SE Wald df P Exp(B) 
Syndecan 1 
(epitelial 
neoplastic 
cells) 
0.676 0.339 3.973 1 0.046 1.967 
Syndecan 1 
(stroma) 
0.473 0.415 0.011 1 0.917 1.044 
Syndecan 2 
(epitelial 
neoplastic 
cells) 
-0.616 0.898 0.471 1 0.493 0.540 
Syndecan 2 
(stroma) 
0.485 0.249 3.787 1 0.052 1.624 
Table 2. Summary of the Cox regression model in all patients with OSCC. 
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The same analysis, repeated on patients with received subsequent adjuvant radiotherapy (total 
44 cases) revealed a stronger association between SYN-1 expression and reduction of overall 
survival. In such analysis we can appreciate 0.023 p-value with 3.479 odds radio: herein the 
statistical association is much stronger than the previous one. Then we can reasonably 
conclude that, in patients submitted to adjuvant radiotherapy, the immunohistochemical 
expression of SYN-1 in neoplastic cells, significantly decreases the overall survival. This is 
the summary of the analysis (Table 3). 
 B SE Wald df P Exp(B) 
Syndecan 1 
(epitelial 
neoplastic 
cells) 
1.247 0.548 5.167 1 0.023 3.479 
Syndecan 1 
(stroma) 
0.319 0.635 0.253 1 0.615 1.376 
Syndecan 2 
(epitelial 
neoplastic 
cells 
-0.964 1.049 0.845 1 0.358 0.381 
Syndecan 2 
(stroma) 
0.050 0.325 0.024 1 0.877 1.052 
 Table 3. Summary of the Cox regression model in patients with OSCC who received 
radiotherapy. 
 
In order to better clarify the role of SYN-1 alone in patients who received radiotherapy, a 
univariate analysis of survival was performed. Log-rank test revealed a significant association 
between SYN-1 score and survival (p=0.001).  
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The scoring system in 5 levels, as described before, was important in correctly evaluating the 
exact percentage of neoplastic cells which were positively stained for SYN-1. However, just 
for practical purposes, we tried to subdivide the scoring system for SYN-1 immunoreactivity 
in two major groups: expression more or less than 50% of the neoplastic cell population. With 
this cut-off, the log-rank test confirmed the statistical significance (p=0.019). Herein we can 
appreciate this statistical significance with the two overall survival curves. 
 
In this graph we could graphically evaluate that, if SYN-1 expression was more than 50% 
(green line), the survival was significantly reduced. On the contrary, if SYN-1 
immunoreactivity was less than 50% (blue line), the overall survival was significantly 
increased. 
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In summary, such association between SYN-1 and overall survival became stronger after 
repeating the same analysis only in patients who received radiotherapy. In this view, SYN-1 
may be considered not only as a prognostic factor, but also as a predictive factor for 
responsiveness to adjuvant radiotherapy. 
 
Other interest results were obtained in considering the disease-free survival curves, in 
examining the role of radiotherapy. We noted a significant reduction in disease-free survival 
for patients who received adjuvant radiotherapy (p=0.021). 
 
 
In this graph the green line represented patients who received radiotherapy. This group of 
patients showed a significant reduction in disease-free survival. This apparently paradoxical 
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result is explained by the fact that radiotherapy is usually administered in patients affected by 
OSCC at advanced stage; these patients would certainly display an adverse prognosis in 
comparison to the other group.  
Unfortunately, the role of chemotherapy was not examined, due to the fact that a very small 
number of patients received this type of treatment. In fact, only 6 patients were treated with 
this adjuvant chemotherapy; this number was too few for any type of statistical consideration. 
 
Discussion 
Cell adhesion molecules, such as integrins, cadherins and cell-surface glycoproteins, are 
involved in many phases of the cell cycle, in differentiation, migration and in many different 
stages of neoplastic development (123-126).  
The major cell surface PGs are syndecans and glypicans (105;106). The syndecan (SYN) 
family comprises four integral membrane proteins, named SYN-1, SYN-2, SYN-4 and SYN-4 
(107). In the glypican (GPC) family there are six family members, known as GPC-1, GPC-2, 
GPC-3, GPC4, GPC-5 and GPC-6 (108). Another important cell surface proteoglycan is NG2 
(109;110). 
Cell surface PGs play an important role, nor only in cellular development, but also in many 
neoplastic diseases (111;112). In OSCC, some researchers have focused on SYN-1 (also 
known as CD138) immunoreactivity as a prognostic factor. Inki et al. have studied 29 patients 
affected by squamous cell carcinoma of the head and neck and they found significant 
association between SYN-1 immunohistochemical expression and grade of differentiation; 
overall survival and recurrent-free survival were reduced in patients with low SYN-1 
expression (113). Anttonen et al. have analyzed 175 patients affected by squamous cell 
carcinoma of the head and neck; they have noted important associations between SYN-1 
expression and histological grade, stage, tumor size; they also have described a significant 
reduction of overall survival in patients with reduced (<80%) expression of SYN-1. 
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Our results are apparently in contrast with these two previous studies, because our data 
suggested that an increased SYN-1 expression was associated with reduced overall survival. 
Nevertheless, these two studies considered all squamous cell carcinomas of the head and neck 
region. In our study, we collected only the tumors of the oral cavity. Furthermore, other 
studies performed upon tumors in the head and neck area and in other districts showed similar 
conclusion to ours. For example, Chen et al. revised 157 nasopharingeal carcinomas and 
found that tumors with SYN-1 expression showed reduction of overall survival in comparison 
to tumors negative for SYN-1. Barbareschi et al. found an association between high SYN-1 
expression and a a more aggressive phenotype in breast neoplasias (127). Other studies found 
high SYN-1 expression in association with poorer prognosis or aggressive phenotypes, in 
prostate neoplasias (128), and in thyroid carcinomas (129). 
All these previous studies reported conflicting results on the role played by SYN-1 as a 
prognostic marker. In this view, our data may help in understanding future studies. 
Furthermore, this association between SYN-1 and prognosis was not only found in all cases 
with available follow up, but it was much more increased when calculated in patients which 
underwent radiotherapeutic treatment (p-value 0.023; odds ratio 3.479). This increased 
association not only confirmed the role of SYN-1 as a prognostic factors, but it introduces 
also the possibility to consider SYN-1 as a predictive factor for establishing the 
responsiveness to radiotherapy. To be a confirmed as a predictive role as responsiveness to 
radiotherapy, a randomized study may be performed. 
SYN-1 expression was also studied in the stroma by Mukunyadzi (115), who found an 
increased expression in invasiveness foci, but without any association with prognosis. We 
also evaluated the stroma, and found no association with prognosis. Other cell surface PGs 
have been studied in the literature. SYN-2 has been evaluated in neoplastic cell culture studies 
and may function as a cell surface receptor in highly migratory tumor cells (116). Some 
authors have demonstrated that GPC-3  could act as a tumor suppressor gene (117;118) . In 
culture cell studies, NG2 expression is related to tumor initiations and growth rate, 
predisposing to poorer prognosis (119). In our study, with all the other markers (except SYN-
1) we did not found any statistical association. 
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The last analysis conducted was the disease-free survival curves upon patients with 
radiotherapy against patients which received no adjuvant treatment. This analysis was carried 
out in order to better clarify the two groups of patients; if different results had been 
discovered, further analyses would have been performed and possible association with PG 
expression investigated. Nevertheless, even if statistical associations were found, they totally 
lacked any clinical significance. As explained before, this apparently paradoxical result is 
explained by the fact that radiotherapy is usually administered in patients affected by OSCCs 
at advanced stage; these patients would certainly display an adverse prognosis in comparison 
to the other group. This is an example of a statistically but not clinically significant result. 
The last consideration is for the recent perspectives upon the role of HPV infection in the 
development of OSCC. It is now clear that HPV, and in particular the high risk type 16 (HPV-
16), play a central role in the oncogenetic process (130). The OSCCs associated with HPV are 
predominantly localized in the palatine tonsil and lingual tonsils of the oropharynx and are 
usually not-keratinizing, mainly of basaloid type. OSCCs associated with HPV affect 
predominantly young patients, with no other known risk factor for OSCC (alcohol and 
tobacco) and carry a significant better prognosis. In our data, HPV infection was not analyzed 
and is currently under investigation in the University of Pavia for another research project. 
Nevertheless, the cases we selected were mainly localized on the oral cavity and not in the 
oropharynx. Furthermore, it is becoming more and more difficult to discriminate which is the 
real role played by HPV in OSCC. HPV is a ubiquitous infection and even its detection may 
represent only a superimposed infection, especially for the low risk types. 
In conclusion our study demonstrated that: 
1. SYN-1 is a prognostic factor, since it is significantly increased in OSCCs with poor 
prognosis, with reduction of overall survival. 
2. This association between SYN-1 and overall survival is much stronger in patients with 
subsequent adjuvant radiotherapy 
3. SYN-1 may be a predictive factor of responsiveness to adjuvant radiotherapy. 
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Epidermal Growth Factor Receptor (EGFR) is a trans-membrane receptor with tyrosine 
kinase activity that plays a central role in regulating cell growth and differentiation, both in 
normal and neoplastic cells (131). In patients affected by non-small cell lung cell cancer 
(NSCLC), specific mutations of the EGFR gene correlate with pathological features and 
responsiveness to tyrosine kinase inhibitors (TKIs) such as gefitinib (14) and erlotinib (15). In 
EGFR-mutated lung adenocarcinoma, gefitinib is superior to carboplatin-paclitaxel therapy 
and EGFR mutations strongly predict outcome after therapy (132). Mutational status of the 
EGFR gene is of thus of primary importance in defining therapeutic decisions (133). 
The mutational spectrum of EGFR in lung adenocarcinomas is variable including in-frame 
deletions, in-frame insertions/duplications and point mutations. The two most common 
genetic changes are an in-frame deletion in exon 19 at codons 746 to 750 (E746-A750 
deletion) and the substitution of leucine 858 by arginine (point mutation L858R) in exon 21 
(134). Together, these two mutations account for approximately 90% of the cases and are 
termed “classical” mutations (135). The gold standard technique for identifying EGFR 
mutation is direct DNA sequencing of PCR-amplified regions of exons 18, 19, 20, 21 (133) 
but its clinical application is limited due to problems of tissue conservation and sampling, 
costs and technical difficulties.   
Recently, two novel antibodies that specifically recognize the E746-A750 deletion in exon 19 
and the L858R point mutation in exon 21 have been described (136). As 
immunohistochemistry (IHC) may represent a faster, more economic and more widely 
applicable alternative to DNA sequencing, the aim of the present study was to compare the 
two procedures in a series of pulmonary adenocarcinomas. 
 
Materials and Methods 
We retrieved from our files all 18 cases of advanced pulmonary adenocarcinomas with EGFR 
mutations and 15 cases with wild-type EGFR. Specimens were routinely fixed in buffered 
EGFR MUTATION-SPECIFIC ANTIBODIES IN PULMONARY 
ADENOCARCINOMA: A COMPARISON WITH DNA DIRECT SEQUENCING 
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formalin and embedded in paraffin.  Sections (4 µm) were stained with haematoxylin and 
eosin for histological diagnosis.  All cases were morphologically reviewed and classified 
according to the most recent IASLC guidelines for lung adenocarcinomas; in each case the 
prevalent pattern of growth was recorded (137).  Immunostaining using a panel of antibodies 
(138) was performed in selected cases, especially in the metastatic lesions and in the small 
endoscopic biopsies, to confirm histotype and pulmonary origin of the lesion.  
Representative blocks were selected for each case, additional unstained sections were 
obtained and both molecular and immunohistochemical analyses were performed.  
 
Molecular analysis 
Tumor tissue was micro-dissected from formalin-fixed paraffin-embedded (FFPE) sections to 
obtain samples with at least 50% of neoplastic cells and genomic DNA was extracted. PCR 
amplification of exons 18, 19, 20, 21 of EGFR was performed using previously described 
primers (14). Amplicons were sequenced and analyzed on both forward and reverse strands; 
mutations were verified in two independent experiments. 
 
Immunohistochemical analysis  
IHC sections (4 µm) were stained with the following primary antibodies: EGF Receptor, 
E746-A750del Specific (6B6) at a working dilution of 1/200 and EGF Receptor, L858R 
Mutant Specific (43B2) at a working dilution of 1/200 (Cell Signaling Technology, Inc, 
Danvers, MA, USA). Each case was tested with both antibodies. For antigen retrieval, 
sections were treated with pH 9 Tris-EDTA buffer for 30 minutes in water-bath at 98°C. The 
slides were developed in diaminobenzidine (DAB) using the HRP Polymer (Ultravision LP 
Large Volume Detection System; Lab Vision, Fremont, CA, USA) in accordance with the 
manufacturer’s specifications and were counterstained with hematoxylin.   
Immunoreactivity was determined with the following scoring system, as previously described 
(139): 0=no staining or faint staining intensity in < 10% of tumor cells; 1+=faint staining in 
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>10% of tumor cells; 2+=moderate staining, 3+=strong staining.  In differentiating score 1+ 
from score 2+, we found useful the presence of membrane reinforcement. Cases with faint, 
diffuse cytoplasmic staining were classified as 1+, while cases with moderate staining and 
focal membrane reinforcement were classified as 2+. Distinction between 1+ and 2+ is 
crucial, because the subsequent statistical evaluation considered 1+ as negative and 2+, 3+ as 
positive for EGFR mutational status. The IHC scoring system is summarized in this Table 4. 
Cases were further classified on the basis of the pattern of immunoreactivity: patchy or 
diffuse, comparing different areas of the same slide.  
 
IHC score Reactivity Membrane 
reinforcement 
Mutational status 
 
0 no staining or faint 
staining intensity in  
< 10% of tumor cells  
no not consistent with 
mutation 
 
1 faint staining intensity 
in >10% of tumor 
cells  
no 
2 moderate staining 
intensity 
focal consistent with 
mutation 
 
3 strong staining 
intensity 
focal or diffuse 
Table 4. Immunohistochemical scoring system. 
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Statistical analysis 
Sensitivity and specificity of IHC were calculated using the molecular status as reference. The 
agreement between the two techniques was calculated with Coehn’s kappa. In comparing the 
two techniques, IHC scores 0 and 1+ were considered as negative for mutational status, while 
IHC scores 2+ and 3+ were interpreted as positive, as already suggested by Kawahara et al. 
(140). All data were analyzed with SPSS 13.0 for Windows. 
 
Results 
We evaluated 33 cases of lung tumours that had been previously analyzed for EGFR 
mutations. There were 21 females and 12 males, with age ranging from 48 to 78 (mean 62.0 ± 
10.6). All cases were lung adenocarcinomas, 23 primaries (5 endobronchial biopsies, 18 
pulmonary surgical resections) and 10 metastatic (7 pleural biopsies, 1 hepatic biopsy, 1 
axillary lymph node resection, 1 cerebral metastasis resection). The prevalent pattern of 
growth was acinar in 17 cases (in 3 of them with extensive mucinous features), lepidic in 2, 
papillary in 3, solid in 11. In 1 case, a small cell neuroendocrine component was associated; 
another case exhibited focal squamous differentiation. 
By conventional DNA sequencing, 12 cases had EGFR mutations in exon 19 and 6 in exon 
21. In exon 19, we considered 9 cases with E746-A750 deletion and 3 cases with alternative 
in-frame deletions: 1 with L747-T751del in homozigotic status, 1 with L747-P753del, 1 with 
E747-S752del. In exon 21, we examined 5 cases with point mutation L858R, and 1 case with 
alternative point mutation L861Q+L862L. The tumor with small cell neuroendocrine 
component exhibited the L858R point mutation in the glandular component. The tumor with 
squamous cell differentiation was examined in the glandular component and was EGFR wild-
type. Furthermore, 15 EGFR wild-type cases were evaluated as negative controls. 
Overall, there were 11 cases with strong staining (2+ and 3+ scores), 4 with weak staining 
(score 1+) and 18 cases that showed no immunoreactivity. Staining was diffuse in 13 cases 
and patchy in 2 cases. Patchy staining was observed in 1+ cases, whereas in 2+ and 3+ cases 
the percentage of stained cells was always more than 70%.  
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The E746-A750del specific antibody detected 6 of 9 cases with E746-A750del mutation (5 
with score 3+, 1 with score 2+) whereas it was negative in three cases (2 with score 1+, 1 with 
score 0) (kappa=0.744, sensitivity: 66.7%, specificity: 100%). The three cases with alternative 
mutations on exon 19 were negative. Overall, 6 of 12 of cases with exon 19 mutations were 
identified (kappa=0.560, sensitivity: 50%, specificity: 100%). 
The L858R specific antibody correctly classified all five cases with the corresponding gene 
mutation (4 with score 3+, 1 with score 2+) (kappa=1, sensitivity: 100%, specificity: 100%) 
(Figure 4). The case with the alternative exon 21 mutation L861Q+L862L was negative.  
Overall, 5/6 cases with mutations in exon 21 were detected (kappa=0.891, sensitivity: 83.3%, 
specificity: 100%). 
All immunoreactive cases were negative when tested with the second antibody. All 15 EGFR 
wild-type control cases were negative with both antibodies (100% specificity). Among them, 
two cases exhibited score 1+ immunoreactivity with the E746-A750del specific antibody, 
whereas all remaining tumors scored 0. 
The overall performance of the two mutation-specific antibodies in the 33 tested cases gave a 
kappa value of 0.588, with 61.1% sensitivity and 100% specificity (Table 5). 
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Sensitivity Specificity kappa 
E746-
A750del 
(6B6) 
L858R 
(43B2) 
E746-
A750del 
(6B6) 
L858R 
(43B2) 
E746-
A750del 
(6B6) 
L858R 
(43B2) 
Detection of 
specific 
mutation 
6/9 (66.7%) 5/5 (100%) 100% 100% 0.744 1 
Detection of 
all mutations 
in the same 
exon 
6/12 (50%) 5/6 (83.3%) 100% 100% 0.560 0.891 
Overall 11/18 (61.1%) 100% 0.588 
 
Table 5.  
Summary of sensitivity, specificity and kappa values of EGFR mutation-specific antibodies 
compared with molecular detection. 
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Figure 4. Immunohistochemical expression of EGFR, detecting mutation L858R on exon 
21.  In case N. 16 the L858R specific antibody strongly and intensely stains the neoplastic 
glands; membrane reinforcement is detectable (bottom) (score 3+, consistent with mutation).
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Discussion 
The comparison between molecular and immunohistochemical methods of EGFR mutations 
detection in lung adenocarcinomas demonstrated two main points: 
1. the L858R antibody had higher sensitivity than the E746-A750del antibody 
2. IHC showed very high specificity (100% in each comparison), but lower sensitivity 
(ranging from 61.1% to 100% in the different comparisons).  
The antibody L858R had 100% sensitivity in detecting L858R mutation on exon 21 and was 
completely negative in the case with the alternative point mutation L861Q+L862L on the 
same exon. The antibody E746-A750del was less sensitive, as it detected 6 of 9 cases with the 
specific mutation and 6 of 12 cases with all mutations in exon 19.  
Previous studies with the same antibodies reported conflicting results (Table 6). Kawahara 
(140) described lower sensitivity for the anti E746-A750del antibody (75%), whereas Brevet 
(139) , Kato (141) and Kitamura (142) found lower sensitivity for anti-L858R antibody (94%, 
75%, and 32%, respectively). Overall, the sensitivity values obtained in the different studies 
are comparable to ours. Nevertheless, Kitamura et al reported 32% sensitivity for L858R 
(142); this study has been performed using tissue microarrays (TMA), whereas we used whole 
sections, probably allowing us a more complete evaluation of the tumoral immunoreactivity. 
In our series, immunoreactivity was sometimes variable in different neoplastic areas; 
therefore, use of whole sections is advisable to avoid false negative results. However, we did 
not consider patchy staining and, in positive cases, immunoreactivity was always more than 
70%. All previous studies are concordant in showing higher specificity (from 92% to 100%) 
than sensitivity (from 39% to 100%) for both antibodies (139-144). Similarly, in our series we 
described very high specificity (100% in each comparison), but lower sensitivity (ranging 
from 61.1% to 100% in the different comparisons).  
In determining EGFR immunoreactivity, one of the crucial points was to differentiate score 
2+ from 1+, because 2+ was considered positive for mutational status and 1+ negative, as 
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previously suggested by Kawahara et al. (140). However, the frequency of 2+ staining is low 
as it was detected only in one case with the antibody L858R and in one case with the antibody 
E746-A750del. In these cases, 2+ and 1+ immunoreactivities could be reliably distinguished 
by staining intensity, percentage of positive cells and membrane reinforcement. 
IHC has distinct advantages over standard sequencing methods. First of all, it is less 
expensive and is more widely available. Secondly, IHC is a rapid procedure and time is 
critical in treating advanced pulmonary neoplasms. Thirdly, IHC may provide reliable results 
even on limited amount of material, i.e. small biopsies or cytological samples. Kawahara et al. 
(145), have reported 100% sensitivity and 100% specificity in a series of 24 patients with 
cytological samples composed of pleural effusions and cerebrospinal fluids. Finally, IHC 
allows to detect the tissue distribution of the mutated cells. This might be useful to evaluate 
cases with combined histology and to improve correlation of mutational status with 
pathological features (8). 
Considering the high specificity of the test, IHC may be used for up-front selection of patients 
which could benefit from TKI therapy, reserving DNA sequencing for negative and/or 
suspicious cases. A similar strategy is currently applied in breast carcinomas for Cerb-B2 
testing.  Cerb-B2 is initially evaluated by IHC that can provide negative, positive or 
ambiguous results; in the latter case (score 2+) further molecular studies, i.e. fluorescence in 
situ hybridization (FISH), are performed (2).  Other mutation-specific antibodies are currently 
being evaluated for clinical use, such as antibodies detecting EML4-ALK gene fusion 
products (146). 
In conclusion, mutation-specific EGFR antibodies are sufficiently accurate to be used in 
routine practice to perform a first-line screening of patients candidate to TKI-therapy, as they 
are less expensive and time-consuming than traditional DNA sequencing. DNA sequencing 
analyses should be always performed in negative or suspicious cases.  
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Ref. (N.) N. of 
cases 
studied 
IHC 
methodology 
Genetic/molecular 
test used 
IHC 
scoring 
criteria 
Sensitivity in detecting EGFR mutations 
E746-
A750del 
antibody in 
identifying 
the specific 
mutation 
E746-
A750del 
antibody in 
identifying 
mutations 
of exon 19 
L858R 
antibody in 
identifying 
the specific 
mutation 
L858R 
antibody in 
identifying 
mutations 
of exon 19 
Brevet et 
al (139) 
218 TMA PCR-RFLP assays 
and sequencing for 
selected cases 
4 
grades, 
visual 
scoring 
20/20 
(100%) 
17/35 (49%)  17/18 (94%) NS 
Kawahara 
et al (140) 
45 Individual 
slides 
Exons 19 and 21 
sequencing 
4 
grades, 
visual 
scoring 
9/12 (75%)  10/19 (53%)  15/19 (79%)  No 
alternative 
mutations 
Kato et al 
(141) 
70 TMA Exons 18 to 21 
sequencing 
H score, 
cut off 
values 
at 20 
9/11 
(81.8%) 
9/18 (50%) 9/12 (75%) No 
alternative 
mutations 
Kitamura 
et al (142) 
238 TMA Exons 19 and 21 
sequencing 
4 
grades, 
digital  
scoring 
NS 16/41 (39%) NS 12/37 (32%) 
Simonetti 
et al (143) 
78 Individual 
slides 
Exons 19 and 21 
sequencing 
4 
grades, 
visual 
scoring 
17/17 
(100%)  
17/29 (59%) 
29 (69%) 
25/25 
(100%)  
25/27 (93%)  
Ilie et al 
(144) 
61 TMA Exons 19, 20 and 21 
sequencing 
4 
grades, 
visual 
scoring 
8/8 (100%) 8/9 (89%) No 
mutations 
in exon 21 
No 
mutations in 
exon 21 
Current 
study 
33 Individual 
slides 
Exons 18, 19, 20 and 
21 sequencing 
4 
grades, 
visual 
scoring 
6/9 (66.7%) 6/12 (50%) 5/5 (100%) 5/6 (83.3%) 
Table 6. Summary of all previous reported studies. Legend: TMA tissue micro array, RFLP 
restriction fragment length polymorphism, NS not specified. 
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